CNBC Investing Club: Cramer’s Morning Take on Tech's Decline 7/7/26

SPEAKER_1 (0:00)

The board recommends approving.

SPEAKER_2 (0:01)

Regarding that seat on the committee, we're promoting to most quarterly earnings.

SPEAKER_1 (0:04)

Every day, shareholders meet to discuss important matters about the companies you invest in. Now you can easily make your voice heard. Vanguard Investor Choice gives you a say in the companies you invest in. With just a few taps, you can set your proxy voting preference for your index funds. Visit vanguard.com/investorchoice to learn more. Vanguard Investors own shares of our index funds, which own shares of the companies they invest in. Available for Vanguard index funds that participate in Investor Choice, Vanguard Marketing Corporation Distributor.

SPEAKER_2 (0:30)

Buy the dip and save on CNBC Pro. 24-7 access to market moving news and interviews across three global live streams for $59.99 at cnbc.com/joincnbcpro.

Terms and conditions apply.

Jim Cramer (0:47)

Jim Cramer here to share a short preview of my take on the market from today's members-only CNBC Investing Club morning meeting. Join the club for full access to the morning meeting every day at 1020 a.m. Visit cnbc.com/morningtake to sign up today. That's one word, morning take.

Jeff Marks (1:08)

So what do you think? How would you handle this rotation then?

Jim Cramer (1:11)

Okay, I think you go against it. I think you buy the stocks that are down the most. I think that you buy Intel, you buy Givernova, buy Moa once, that would be a mistake.

Because we'll find out, there will be a piece soon enough, somebody, something will have written something which just says CPUs are in short supply, and you've got to buy Intel. Their foundry system is better than expected. I mean, this is what happens. You get caught up in the negativity. You see SpaceX down, and you say, look, the hell with this. I don't know what to do anymore. Because I got into SpaceX and I got lucky, and now I'm obviously not lucky.

I say, just be cool. This is a long-term play, and I don't mind what any of the analysts reports. It's just that right now, this is a UNH CVS market, and it's a Cardinal Health market. And the market doesn't seem to have more money for anything but that.

Jeff Marks (2:07)

Yeah, and our Pharma name is doing well. Also J&J, New High. Look at J&J right here.

While Bristol flat since our sale. So a good upgrade of the portfolio as we planned it.

Jim Cramer (2:18)

Yeah, I mean J&J is most likely going to have a good quarter. It's actually breaking away. But the multiple is still very low.

Jeff Marks (2:25)

And then Eli Lilly gets its price target raised to $1400 from $1300 at JP Morgan. It's a 2Q preview, and they expect strong, better than expected GLP1 sales, specifically Manjaro internationally as a source of upside. Foundeo though, which is the oral GLP pill. Well, they're looking more at the fourth quarter as well as sales will begin to ramp. It has been slower than Wigovia, of course, or Wigovia had that first mover advantage, being launched first. It also had the benefit of having the same brand name as the injectable Foundeo new molecule. So a little bit different there, but Lilly having a nice move back to the highs here.

Jim Cramer (3:06)

I understand Lilly is just a reiteration with a slight boost of earnings. It doesn't matter. In this market, that's fuel.

That's fuel to really make a lot of money.

SPEAKER_5 (3:16)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates, and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. To view the full CNBC Investing Club disclaimer, please visit cnbc.com/investingclubdisclaimer.

SPEAKER_2 (3:48)

Buy The Dip and save on CNBC Pro. 24-7 access to market moving news and interviews across three global live streams for $59.99 at cnbc.com/joincnbcpro.

Terms and conditions apply.